Word: lichtenfeld
(lookup in dictionary)
(lookup stats)
Dates: all
Sort By: most recent first
(reverse)
...support the benefit of routine screening when balanced with risks, among younger women. The new recommendations are also backed by some prominent physicians, including the cancer surgeon Dr. Susan Love, who agree there's insufficient data to show that screening under 50 works. The debate, says Dr. Len Lichtenfeld of ACS, is not likely to end soon. "This is the beginning of a discussion that will likely continue vigorously over the next several months, if not years," he predicts...
...Society holds firm to its position - recommending yearly mammograms for women beginning at age 40 - adamantly stating that it will not modify its guidelines. "We are not changing current recommendations at this time based on our initial review of the information provided by the task force," says Dr. Len Lichtenfeld, deputy chief medical officer for the ACS. (See pictures from an X-ray studio...
...connection with reality,” his new paper reads. “Could it be that [African-Americans] believe in the myth twice as frequently as [European-Americans] because they observe it twice as often?” Retsky’s research is again raising eyebrows. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society, said he was skeptical. “The problem here is, there is little evidence provided to back up the claim. It is a theory, not a study supporting the theory, but simply a theory,” he wrote...
...clinical uncertainties need to be addressed as well. Tamoxifen reduces the risk of noninvasive breast cancers (ductal carcinoma in situ and lobular carcinoma in situ), while raloxifene does not. "Expert opinion is going to be very important in interpreting this," says Dr. Len Lichtenfeld of the American Cancer Society. "We're certainly looking forward to all the information being examined and discussed...
Having said that, Lichtenfeld notes that the STAR trial is a scientifically rigorous, well-controlled study that involved nearly 20,000 women and was conducted by very reputable researchers. More data will be presented in June at the annual meeting of the American Society of Clinical Oncology. The investigators are also writing a paper to submit to a research journal, but felt it would be unethical to withhold from the group that participated in the STAR trial their overall conclusion that raloxifene was the winner. The women will now find out which drug they were taking, and those on tamoxifen...